OR WAIT null SECS
Nottingham location expected to be fully operational by the end of 2023
Upperton Pharma Solutions, a UK contract development and manufacturing organization (CDMO), announced that construction has commenced on its new development and good manufacturing practice (GMP) headquarters in Nottingham. The 50,000 square-foot site, which is being built with the assistance of contractor T-SQUARED, broke ground earlier this month, and is expected to be ready by the end of the year.
According to the company, the new plant will expand upon its current manufacturing capabilities by featuring 10 new GMP manufacturing suites, quality control laboratories, and dedicated analytical and formulation development laboratories with pilot plant facilities. By the end of 2024, Upperton expects to create an additional 150 jobs in the region.
The Nottingham location reportedly will be able to handle a range of dosage forms including solids, liquids, semi-solids, nasal, and inhaled products. Upperton adds that it will support early formulation development, provide clinical trial supplies from Phase I to Phase III, and niche-scale commercial manufacture.
“ … This plant has been in the planning for almost 12 months, so to see the plans finalized and work start on the site is hugely satisfying not only to us as a business, but also for our customers, as we can now offer them a seamless transition from early development to clinical trials and commercial manufacturing, all at one site,” notes Nikki Whitfield, Upperton CEO.
Read more about the plans for the new facility here.